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Breast cancer cases diagnosed in women aged 50–69 since 1990 to 1996 in the City of Florence were partitioned into those
who had been invited to screening prior to diagnosis and those who had not. All cases were followed up for vital status until
31 December 1999. The cumulative number of breast cancer deaths among the cases were divided by screening and
invitation status, to give the rates of cancers proving fatal within a period of 8 years of observation (incidence-based mortality).
We used the incidence-based mortality rates for two periods (1985–86, 1990–96), pre and during screening. The incidence-
based mortality ratio comparing 1990–96 and 1985–86 was 0.50 (95% CI:0.38–0.66), a signiﬁcant 50% reduction. For
noninvited women, compared to 1985-86, there was a 41% signiﬁcant mortality reduction (RR=0.59, 95% CI:0.42–0.82). The
comparable reduction in those invited was a signiﬁcant 55% (RR=0.45, 95% CI:0.32–0.61). The incidence ratio of rates of
cancers stage II or worse was close to one when the noninvited in 1990–96 were compared with 1985–86 (RR=0.97, 95%
CI:0.78–1.21). Excluding prevalent cases, the rate of stage II+ breast cancer cases was 42% lower in Screened women
compared with the noninvited (RR=0.58, 95% CI:0.45–0.74). This study conﬁrmed that new treatments and the ﬁrst rounds
of the screening programme contributed to reducing mortality from breast cancer.
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Following the demonstration by randomised clinical trials that
mammographic screening reduces mortality for breast cancer,
population-based breast cancer screening programmes have been
initiated in many countries and the challenge today is to evaluate
the effectiveness of these programmes in the routine health care
environment. To accomplish this task is difﬁcult, due partly to
the many factors inﬂuencing the incidence, staging and mortality
for breast cancer and partly to the complexity of data collection.
Many attempts have been made to analyse breast cancer mortality
rates in relation to the introduction of screening programmes.
Simple comparisons of mortality rates before and after the intro-
duction of screening is biased by confounding with other
changes over time (for example in therapy), and by the inclusion
of deaths from tumours diagnosed before the introduction of
screening. Blanks et al (2000) solved the ﬁrst of these problems
by comparing changes in cohorts likely to have been invited to
screening with those in cohorts unlikely to be invited. They noted,
however, that the second problem remains, that including deaths
from cancers diagnosed before screening was available.
Tabar et al (2001) considered deaths in each period only from
tumours diagnosed in that period and compared changes over time
in age groups exposed to screening invitation with those in age
groups which were never invited to screening, thus addressing both
problems. In addition, they identiﬁed the women who were actually
screened and estimated the effects of actually receiving screening as
well as of invitation to screening, adjusting for selection bias and
lead time. The analysis presented in this paper is based on the data
of the Tuscany Tumour Registry which has been operating since
1985 and includes the City of Florence where population-based
breast cancer screening programmes started in 1990.
Using standard methods a mortality reduction of 19% for
invited women by the screening programme was estimated (Paci
et al, 2002).
MATERIALS AND METHODS
Breast cancer cases diagnosed in women resident in the City of
Florence were registered by the Tuscany Tumour Registry accord-
ing to the IARC rules for cancer registration (Berrino et al, 1995).
Cases ascertained only from death certiﬁcates and multiple
primaries were excluded. The Florence City screening programme
and main performance indicators have been described in detail
(Giorgi et al, 1994). The target population was the resident female
population aged 50–69 years, who were invited over the period
from 1990–96 to have 2-view, high quality mammography every
2 years.
All breast cancer cases were linked to the screening database and
partitioned by ‘detection’ category as follows:
(1) Cases diagnosed in the ﬁrst round of screening or in a woman’s
ﬁrst test at a subsequent round, viz. prevalent screen detected
cases.
(2) Cases detected at repeat screening tests or detected clinically
after a negative screening test but before the subsequent
invitation or the end of the study period.
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(4) Cases diagnosed in women eligible but not yet invited to
screening (since it took several years to achieve full coverage of
the population with invitation to screening) or of uncertain
diagnostic modality.
In the comparison of mortality of invited and non-invited
women, the ﬁrst three categories were combined to form the
invited group and compared with the noninvited. In the compar-
ison of screened with unscreened women, the ﬁrst two categories
only were combined to give the screened group and the second
two to give the unscreened. All breast cancer incident cases were
followed up for vital status until 31 December 1999 and the
underlying cause of death collected. The 50–69 years old female
population by calendar year was identiﬁed from the records of
the municipality of Florence. All resident women in the age range
received an invitation in the enrolment period or at the ﬁrst
subsequent round, if eligible. For each woman from January
1990, the starting date of the programme, we calculated the
person-years lived before the date of ﬁrst invitation (noninvited).
After the invitation, the women-years at risk of breast cancer
(invited) were calculated to the end of the study period (31
December 1996), diagnosis of breast cancer, exit from the target
population on reaching the age limit (70th birthday), death or
migration. Invited women were further divided into respondents
(screened) and non respondents to the invitation. The statistical
analysis was performed using Stata (Stata Statistical Software,
2001).
The tumour characteristics were reviewed and size classiﬁed as
T1a, T1b,T1c or T2+, nodal status as negative or positive and
stage according with the UICC-pTNM. Stage II+ tumours were
considered as advanced cases. In addition we examined the 5-year
cause speciﬁc survival by stage. Missing data refer to the non-
operated and the unknown. Full data on tumour characteristics
were not generally available before 1990. The 1985–86 data had
been reviewed for purposes of a previous study and incidence
and case- fatality rates speciﬁc to the 1990–96 target population
were therefore compared to the 1985–86 data (Paci et al, 1994).
To estimate the impact on mortality we used a method like that
of Tabar et al (2001) and to the estimate of the Incidence-based
mortality (IBM), developed by Chu et al (1994). All breast cancer
deaths among the cases diagnosed after the ﬁrst invitation (invited
women) and until 31 December 1999, were included in the calcu-
lation of the IBM rate, estimated as the rate of fatal incident
cases.
Given that enrolment lasted from September 1990 to early
1993, an average duration of observation of 8 years (from
1992–1999) was assumed for invited women. The occurrence of
breast cancer deaths within breast cancer cases in 8 years of
follow-up was considered for comparison. Deaths from 1990–
1997 of noninvited breast cancer cases and from 1985–1992 in
cases diagnosed in the period 1985–86, were included in the
calculation of the IBM rate. The same 8-year follow-up time from
the year of the start of the observation period for all groups was
intended to eliminate the lead time bias due to the earlier diagno-
sis in screened women: breast cancer death rates would have been
similar for the three groups in the absence of treatment or screen-
ing beneﬁt. (Figure 1).
The IBM rate is not equivalent to the usual mortality rate
because the population at diagnosis rather than at death forms
the denominator; in addition, it relates to the age at diagnosis
rather than age at death; it differs from the case-fatality rate in that
the denominator is population-based and not breast cancer cases.
Although not identical to IBM estimates used by Chu et al
(1994) and applied to interpret trends in prostate cancer in the
US (Feuer et al, 1999), we refer incidence based mortality (IBM)
to our rates below, since IBM seems to be the most accurate
description.
The advantages of using the incidence of tumours proving fatal
are:
(a) That this is not affected by length bias or overdiagnosis, since
excessive diagnosis of indolent tumours does not affect the
number of aggressive tumours; and
(b) With only two periods, pre-screening and during screening, it
is not affected by lead time bias.
RESULTS
In the period 1990–96, 1122 invasive breast cancers and 84 carci-
noma in situ cases were diagnosed in women aged 50–69. In the
same period of time, 35568 women received their ﬁrst screening
test and 35954 a repeat screening test. In 1990–96 there was a
total of 419632 person-years corresponding to approximately
60000 women each year, invited women had 254890 and screened
women 155645 person years after their prevalence test to the end
of follow-up. The corresponding noninvited person-years were esti-
mated as 164742. There were 99425 person-years of observation in
women who were invited but did not attend. In the reference peri-
od 1985–86, 282 invasive breast cancer were clinically diagnosed in
123573 women-years.
Table 1 shows the incidence of breast cancer in women aged
50–69 by period. Between the two periods, the breast cancer inci-
dence rate increased from 2.3 to 2.7 per 1000 women aged 50–69.
This reﬂects the peak in incidence in the early years of screening
due to the prevalence round. The incidence rates were 3.6 and
2.1 per 1000 in screened and unscreened and 2.9 and 2.3 per
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Figure 1 Incidence-based mortality by calendar period and screening
status.
Table 1 Breast cancer incidence and incidence-based mortality (IBM) in
the City of Florence by calendar period
Period 1985–1986 1990–1996
Breast cancers 282 1122
Average population 61 786 59 947
Person-years 123 573 419 632
Incidence/1000 2.3 2.7
Deaths
a 87 149
IBM rates/10 000 7.0 3.6
IBM ratio 1.00 0.50
IBM ratio, 95% CI – (0.38–0.66)
IBM absolute difference 0 73.4
IBM difference, 95% CI (75.1;71.9)
aNote: Breast cancer deaths within cases diagnosed in the two periods, with 8 years
of follow up since the year of start of the period.
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The IBM ratio comparing 1990–96 and 1985–86 for fatal breast
cancer cases within 8 years since the start of the period was 0.50
(95% CI : 0.38–0.66), a signiﬁcant 50% reduction corresponding
to an absolute difference of 73.4 deaths per 10 000 women years.
In Table 2, deaths from cancers diagnosed in 1990–96, person-
years and IBM rates are shown classiﬁed by screening and invitation
status. The IBM rates were 25% less (RR=0.75, 95% CI:0.54–1.04)
for invited compared to noninvited women: and the reduction was
statistically signiﬁcant for screened women (RR=0.63, 95%
CI:0.42–0.94). To estimate the trend in mortality occurring inde-
pendently of screening, we calculated the reduction in the IBM in
noninvited women compared to 1985–86, there was a 41% signiﬁ-
cant reduction (RR=0.59, 95% CI:0.42–0.82). The comparable
reduction in those invited was 55% (RR=0.45, 95% CI:0.32–0.61).
The reduction in breast cancer mortality is related to more
favourable stage distribution and to improved breast cancer speciﬁc
survival rates overall and by stage, presumably due to better treat-
ment and breast cancer care. Incidence rates of advanced tumours
are considered good indicators of the mortality reduction (Tabar et
al, 2001). In order to account for the incidence inﬂation of cases
due to the prevalence screening, rates are presented separately for
cases screen-detected at the prevalence test (the exclusion of preva-
lent cases is marked with * in screened*, invited* and total*
groups). Cases diagnosed at the prevalent screen are most prone
to lead time and over-diagnosis biases and not occur as incident
cancer cases within the study period. The 5-years cause-speciﬁc
survival rates improved from 75% for the 1985–86 breast cancer
cases to 90% in invited (including screen detected cases) and
84% in noninvited women diagnosed in the period 1990–1996.
Forty-two per cent of stage II+ breast cancer cases were detected
earlier by screening in screened* women compared with the nonin-
vited (RR=0.58, 95% CI:0.45–0.74); 28% fewer stage II+ tumours
were observed in the invited* compared with the noninvited
(RR=0.72, 95% CI:0.59–0.87) (Table 3). The 5-year survival rate
was 88% for stage II+ breast cancers detected at the prevalence
screening, suggesting a within-stage lead time. The corresponding
survival rates for stage I cancers were also increased (data non
shown). In the total* group, i.e. excluding cases screen detected
at prevalence, the stage II+ disease rate was reduced by 19%
(RR=0.81, 95% CI:0.67–0.98), but the ratio was near to one when
the noninvited women only were compared with the 1985-86 rate
(RR=0.97, 95% CI:0.78–1.21). The corresponding 5-year survival
rates for stage II+ increased signiﬁcantly from 63% in 1985–86 to
75% in 1990–96 in noninvited women.
Table 4 shows the comparison of the IBM rates for 1985–86
with the noninvited and invited women by stage (5II;II+; miss-
ing). In breast cancer cases stage II+ at diagnosis, the IBM rate
difference was 71.9 per 10 000 person-years (RR=0.63, 95%
CI:0.43–0.92) between the rate observed in 1985-86 and the rate
of noninvited women; a reduction of 71.1 breast cancer deaths
per 10 000 person-years was estimated between invited and nonin-
vited women (RR=0.68, 95% CI:0.46–1.00). For breast cancer
cases staged as less than II at diagnosis, the IBM rate showed a
reduction of 70.75 deaths per 10 000 between the 1985–86 cases
and the noninvited. The IBM rate from stage less than II cancers in
the noninvited women was higher than that in the invited,
although not signiﬁcantly so (RR 1.55, 95% CI:0.51–5.62).
DISCUSSION
The main aim of this paper was to develop a method for evaluating
population-based breast cancer screening programmes using data
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Table 2a Breast cancer deaths within cases diagnosed in 1990–96, per-
son–years and IBM rates by screening and invitation status
Status 1990–96
Screened Deaths
a 41
Person–years 155 645
Rate/10 000 2.6
Not screened Deaths
a 108
Person–years 263 987
Rate/10 000 4.1
Invited Deaths
a 80
Person–years 254 890
Rate/10 000 3.1
Noninvited
b Deaths
b 69
Person–years 164 742
Rate/10 000 4.2
aNote: Breast cancer cases followed up at 31 December 1999 (8 years on average
since the start orf the programme);
bNote: Breast cancer deaths within cases diag-
nosed in 8 years since the year of start of the period (1990).
Table 2b
Rate
a Rate ratio Rate difference
a
Noninvited 4.2 1.00 0.00
Invited 3.1 0.75 71.0
95% CI (0.54–1.04) (72.2: 0.1)
Screened 2.6 0.63 71.6
95% CI (0.42–0.94) (72.8:70.3)
aper 10 000 person years.
Table 3 Stage II+ breast cancer rate and 5-years survival by calendar period and screening status
Total
1985–86
(N=282)
Total*
1990–96
(N=827)
Screen detected
(preval.) 1990–96
(N=295)
Screened*
(N=261)
Unscreened
(N=566)
Invited*
(N=455)
Noninvited
(N=372)
Stage II+ number of cases 150 411 87 107 304 216 195
Per cent of the total 53.2 49.7 29.5 41.0 53.7 47.5 52.4
5-year survival (95% CI)
among stage II+ cases
63
(55–71)
77
(73–81)
88
(78–93)
84
(74–90)
75
(70–80)
80
(73–85)
75
(68–81)
Rate/1000 1.21 0.98 0.21 0.69 1.15 0.85 1.18
aExcluding screen detected, at prevalence screening; Note: missing stage is 14% in 1985–86 and 7.4% in 1990–96.
Table 4 Incidence-based mortality by screening status and stage at diag-
nosis per 10 000 person years (number of deaths in brackets)
1990–96
Stage at diagnosis 1985–86 Noninvited Invited Screened
5II 1.0 (13) 0.3 (5) 0.5 (12) 0.6 (10)
II+ 5.3 (65) 3.3 (55) 2.3 (58) 1.7 (26)
Missing 0.7 (9) 0.5 (9) 0.4 (10) 0.3 (5)
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data with a minimum set of data from the screening services.
The use of IBM measures should prove useful in future evaluation
with longer follow up. A summary of the changes in various IBM
and stage II+ rates between 1985–86 and 1990–96 are given in
Table 5. The incidence of fatal tumours fell signiﬁcantly by 41%
between the 1985–86 reference and the noninvited women, who
were diagnosed after 1990. The IBM rate difference between
1985–86 and the noninvited was 71.92 per 10 000 women with
a stable rate of stage II+ tumours. The increase in survival rates,
comparing the late 1980’s with early 1990’s has been documented
by several cancer registries (Rosso et al, 2001). The 5-years breast
cancer survival increased by 9% when 1985–86 and noninvited
breast cancer cases are compared. Although a shift towards earlier
diagnosis cannot be excluded, this result is a major conﬁrmation of
the impact of changes in breast cancer therapy and care on breast
cancer mortality. Assuming, as estimated by Chu et al (1994), an 8
years lag required for the IBM rates to explain the overall breast
cancer mortality data, the observed IBM rate reduction is probably
in good agreement with the reduction of breast cancer mortality
observed in Florence City in the early 1990s (Barchielli and Paci,
2001).
The reduction from the reference period of 73.9 deaths per
10000 in the invited (and the 74.4 per 10000 less deaths amongst
the screened) when compared with the 72.8 death reduction in
the noninvited, indicates that about one-third of the reduction in
women exposed to screening is due to the screening rounds and
the other two-thirds due to other causes, including therapeutic
innovations. The stage II+ rate reduction for the screened*
(75.2 advanced cases per 10000) suggests that the effect might
increase as the screening process continues and with longer follow
up. These results differ from those of Tabar et al (2001), though
the relative reduction of mortality in the screened group is similar.
That study implied that the majority of the mortality reduction was
attributable to screening. In our study the period of observation is
short and the start of screening followed major changes in therapy
in the eighties.
The proportion of all breast cancer cases which were detected at
screening in the period 1990–96 was in total about 40% of all
cases and the person-years of screened women in this period were
155645 (37% of the total). In order to estimate the number of
deaths saved, we applied the IBM rates in the reference period
(1985/86), for noninvited and invited to the screened women years.
One hundred and eight breast cancer deaths within incident cases
would have been expected applying the IBM rate of the reference
period, and 65 by applying the noninvited IBM rate. Considering
the expected number of incident cases (incidence rate of 2.3 per
1000), 358 breast cancer incident cases were expected in the
absence of screening. The reduction in the number of deaths is
quite comparable to the reduction in the case-fatality rates, though
calculated by a different method. The estimate of the expected
number of deaths using the invited women IBM rate was 49, indi-
cating that the number of deaths saved compared with the
expected applying the noninvited IBM rate, of 16 (intention-to-
treat analysis); applying the IBM rate of screened women gives
the estimated number of lives saved as 24. Among the 35568
women in the ﬁrst screening 0.45 deaths were saved per 1000
screened women if the rate of the invited is applied or 0.67 if based
on the screened women. This result is in agreement with the risk
reduction expected from screening 8 years from the beginning.
Further follow-up will allow more reliable evaluation of the impact
of the screening programme.
With regard to the evaluation of the IBM rates by stage, the
comparison of the 1985–86 IBM rates with the noninvited and
invited in 1990–96 showed a reduction of fatal cancer deaths in
cases diagnosed as advanced. This ﬁnding might be attributable
to the improvement of the case-fatality rate because of better treat-
ment or to a reduction of the rate of stage II+ cancers. The stage
5II IBM rate decreased for noninvited and the invited in compar-
ison with the reference period, but a non-signiﬁcant increase of the
early stage IBM rate was observed between invited and noninvited.
A possible stage shift bias between advanced and less advanced
carcinomas might determine an increase of the IBM rate of less
advanced cases. The small increase so far observed excludes an
important misclassiﬁcation bias of advanced tumours related to
the detection at screening.
Recently breast cancer mortality rates have been used to esti-
mate the possible mortality reduction related to screening in
England and Wales. The result was a 6.4% reduction in overall
breast cancer mortality which was attributed to screening,
approximately one-third of a 20% reduction (Blanks et al,
2000). This estimate, however, was based on modelling breast
cancer deaths regardless of period of diagnosis. Thus deaths from
tumours diagnosed before screening was introduced were included
in the cohorts nominally exposed to screening. It would be inter-
esting to see the results for England and Wales with respect to
IBM. Our data shows that treatment and screening have reduced
breast cancer mortality in Florence, but the full impact of the
screening programme needs a longer follow up and improved
programme performance (compliance rates, interscreening inter-
val). However, we consider that our incidence-based method for
the monitoring of the efﬁcacy of breast cancer screening
programmes is useful and it will be complemented by an evalua-
tion based on the individual screening history. The collection of
details of the screening history for each individual can be difﬁcult.
Irregular participants (and therefore irregular non-participants)
can represent a large proportion of the population. For this
reason, an approach based on sampling, such as a case-control
study, is a possible tool to corroborate the results presented in
this paper and is currently under investigation.
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Table 5 Summary of the incidence-based mortality and stage II+ rate
changes between 1985–86 and 1990–96, by screening status
% Reduction
Absolute rate reduction
(610 000)
1985–86 (Reference) 0 0
IBM
Total (1990–96) 50% 73.4
Noninvited 41% 72.8
Invited 55% 73.9
Screened 63% 74.4
Stage II+ rates
Total (1990–96) 19% 72.3
Noninvited 2% 70.3
Invited* 30% 73.6
Screened* 43% 75.2
Stage speciﬁc IBM
Stage 5II Noninvited 71% 70.75
Stage 5II Invited 55% 70.58
Stage II+Noninvited 37% 71.92
Stage II+ Invited 57% 72.98
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